✦ LIBER ✦

Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience

✍ Scribed by Massimo Breccia; Laura Cannella; Annamaria Frustaci; Caterina Stefanizzi; Anna Levi; Giuliana Alimena

Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 122 KB
Volume: 32
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2007.08.016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Capillary electrophoresis method for pla

Capillary electrophoresis method for plasmatic determination of imatinib mesylate in chronic myeloid leukemia patients

✍ Tatiana O. Ajimura; Keyller B. Borges; Aline F. Ferreira; Fabíola A. de Castro; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB 👁 2 views

Successful treatment of chronic myeloid

Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis

✍ Evren Ozdemir; Yener Koc; Emin Kansu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 285 KB 👁 2 views

Chronic myeloid leukemia in a patient wi

Chronic myeloid leukemia in a patient with chronic idiopathic thrombocytopenic purpura: Rapid response to imatinib mesylate (STI571)

✍ Imashuku, Shinsaku ;Morimoto, Akira ;Kuriyama, Kikuko ;Kano, Gen ;Hibi, Shigeyos 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 46 KB

Brain natriuretic peptide level as marke

Brain natriuretic peptide level as marker of cardiac function in imatinib—Treated chronic myeloid leukemia patients: No evidence of cardiotoxicity of imatinib therapy

✍ Mario Tiribelli; Antonio Colatutto; Luciana Marin; Giuseppe Barbina; Ugo Qualizz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB 👁 2 views

Phase 1 study of lonafarnib (SCH 66336)

Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib

✍ Jorge Cortes; Elias Jabbour; George Q. Daley; Susan O'Brien; Srdan Verstovsek; A 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB 👁 1 views

## Abstract ## BACKGROUND. Lonafarnib is an orally bioavailable nonpetidomimetic farnesyl transferase inhibitor with significant activity against BCR‐ABL‐positive cell lines and primary human chronic myeloid leukemia (CML) cells. Lonafarnib can inhibit the proliferation of imatinib‐resistant cells

Imatinib mesylate induces hypophosphatem

Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response

✍ S. Osorio; A. García Noblejas; A. Durán; J.L. Steegmann 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 2 views